Genscript Biotech Corporation (GNNSF)
USD 1.5
(-21.0%)
USD 1.5
(-21.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.38 Billion USD | 32.99% |
| 2022 | 2.54 Billion USD | 14.05% |
| 2021 | 2.23 Billion USD | 54.26% |
| 2020 | 1.44 Billion USD | 62.74% |
| 2019 | 889.41 Million USD | -3.01% |
| 2018 | 916.97 Million USD | 81.84% |
| 2017 | 504.26 Million USD | 123.09% |
| 2016 | 226.03 Million USD | 24.14% |
| 2015 | 182.07 Million USD | 97.09% |
| 2014 | 92.38 Million USD | 10.19% |
| 2013 | 83.83 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.33 Billion USD | -1.61% |
| 2024 Q2 | 3.33 Billion USD | 0.0% |
| 2023 Q1 | 3.38 Billion USD | 32.91% |
| 2023 Q3 | 3.38 Billion USD | 0.09% |
| 2023 Q2 | 3.38 Billion USD | 0.0% |
| 2023 FY | 3.38 Billion USD | 32.99% |
| 2023 Q4 | 3.38 Billion USD | -0.03% |
| 2022 Q4 | 2.54 Billion USD | 0.0% |
| 2022 Q3 | 2.54 Billion USD | 18.75% |
| 2022 Q2 | 2.14 Billion USD | 0.0% |
| 2022 Q1 | 2.14 Billion USD | -3.96% |
| 2022 FY | 2.54 Billion USD | 14.05% |
| 2021 Q3 | 2.23 Billion USD | 18.32% |
| 2021 Q4 | 2.23 Billion USD | -0.05% |
| 2021 Q2 | 1.88 Billion USD | 0.0% |
| 2021 Q1 | 1.88 Billion USD | 30.44% |
| 2021 FY | 2.23 Billion USD | 54.26% |
| 2020 Q3 | 1.44 Billion USD | 0.53% |
| 2020 FY | 1.44 Billion USD | 62.74% |
| 2020 Q1 | 1.43 Billion USD | 61.88% |
| 2020 Q2 | 1.43 Billion USD | 0.0% |
| 2020 Q4 | 1.44 Billion USD | 0.0% |
| 2019 Q4 | 889.41 Million USD | 0.0% |
| 2019 Q3 | 889.41 Million USD | 0.85% |
| 2019 Q2 | 881.95 Million USD | 0.0% |
| 2019 Q1 | 881.95 Million USD | -3.82% |
| 2019 FY | 889.41 Million USD | -3.01% |
| 2018 Q3 | 916.97 Million USD | 2.15% |
| 2018 Q1 | 897.67 Million USD | 78.02% |
| 2018 Q2 | 897.67 Million USD | 0.0% |
| 2018 Q4 | 916.97 Million USD | 0.0% |
| 2018 FY | 916.97 Million USD | 81.84% |
| 2017 Q3 | 504.26 Million USD | 105.35% |
| 2017 FY | 504.26 Million USD | 123.09% |
| 2017 Q4 | 504.26 Million USD | 0.0% |
| 2017 Q2 | 245.56 Million USD | 0.0% |
| 2017 Q1 | 245.56 Million USD | 8.64% |
| 2016 Q3 | 226.03 Million USD | 5.45% |
| 2016 Q4 | 226.03 Million USD | 0.0% |
| 2016 FY | 226.03 Million USD | 24.14% |
| 2016 Q2 | 214.35 Million USD | 0.0% |
| 2016 Q1 | 214.35 Million USD | 17.73% |
| 2015 Q3 | 182.07 Million USD | 93.35% |
| 2015 Q1 | 94.17 Million USD | 1.94% |
| 2015 Q4 | 182.07 Million USD | 0.0% |
| 2015 FY | 182.07 Million USD | 97.09% |
| 2015 Q2 | 94.17 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 92.38 Million USD | 10.19% |
| 2014 Q4 | 92.38 Million USD | 0.0% |
| 2014 Q3 | 92.38 Million USD | 0.0% |
| 2013 FY | 83.83 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -146596561.342% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -172834.424% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -31986.25% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -613241.824% |
| Rebus Holdings, Inc. | 5000.00 USD | -67727557.54% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -2500.694% |
| Qrons Inc. | 420.00 USD | -806281537.381% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -439322.467% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -12018.461% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -704578.712% |
| Skye Bioscience, Inc. | 11.94 Million USD | -28260.689% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -8617.231% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -46804.356% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -4435008.674% |
| SQZ Biotechnologies Company | 107.18 Million USD | -3059.322% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -236373.967% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -4679486.647% |
| Mesoblast Limited | 667.9 Million USD | -407.019% |
| Marizyme, Inc. | 22.01 Million USD | -15282.109% |
| Genus plc | 1.02 Billion USD | -229.127% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -249200.651% |
| Pharming Group N.V. | 462.85 Million USD | -631.631% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -102114.628% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -678480.808% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -539992.963% |
| ContraFect Corporation | 20.67 Million USD | -16275.951% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -867389.197% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -885977.1% |
| IMV Inc. | 31.33 Million USD | -10707.448% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -81577.88% |
| MultiCell Technologies, Inc. | 126.22 USD | -2682920892.711% |
| ONE Bio Corp. | 70.08 Million USD | -4731.788% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -360272.727% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -2535.112% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -784304.23% |
| Q BioMed Inc. | 3.51 Million USD | -96226.739% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -9526.149% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1295989.161% |
| Biomind Labs Inc. | 73.81 Thousand USD | -4587313.643% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -658.753% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -233630.147% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -11182.32% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -123205.528% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -492474.813% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -129985.59% |
| GB Sciences, Inc. | 103.44 Thousand USD | -3273602.052% |
| Alpha Cognition Inc. | 2.45 Million USD | -137997.394% |
| HST Global, Inc. | 1526.00 USD | -221912277.261% |
| CSL Limited | 38.02 Billion USD | 91.094% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -342662.752% |
| Halberd Corporation | 10.13 Thousand USD | -33425848.84% |
| Enzolytics Inc. | 361.7 Million USD | -836.224% |
| Agentix Corp. | 261.39 Thousand USD | -1295418.944% |
| Resverlogix Corp. | 8.11 Million USD | -41629.918% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -180230.1% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 25.45% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -6999.038% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -529306.881% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -14864843.931% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -37740.253% |
| AVAX Technologies, Inc. | 7.37 Million USD | -45803.63% |
| Zenith Capital Corp. | 7410.00 USD | -45700073.779% |
| Ember Therapeutics, Inc. | 184.00 USD | -1840425376.63% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1052205.699% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1295557.733% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -364827.284% |
| Kadimastem Ltd | 2.3 Million USD | -146873.32% |
| Helix BioMedix, Inc. | 3.02 Million USD | -111843.359% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -6325.652% |
| BioStem Technologies, Inc. | 14.56 Million USD | -23157.659% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -5931141.246% |
| LadRx Corporation | 2.3 Million USD | -146631.197% |
| Cell Source, Inc. | 195.17 Thousand USD | -1734985.067% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -957541.425% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -957541.425% |
| NovAccess Global Inc. | 62.24 Thousand USD | -5440047.277% |
| Affymax, Inc. | 7.44 Million USD | -45397.553% |
| Itoco Inc. | 1.4 Million USD | -241772.052% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -3540030.756% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -3194600.827% |
| Mobile Lads Corp. | 52.00 USD | -6512274663.462% |
| CytoDyn Inc. | 11.13 Million USD | -30309.329% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2368463.689% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -18939401.549% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -878405.225% |
| SYBLEU INC | 330.46 Thousand USD | -1024623.385% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -827013.071% |
| International Stem Cell Corporation | 5.39 Million USD | -62727.141% |
| Bioxytran, Inc. | 137.63 Thousand USD | -2460254.609% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -22473.132% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -20325.737% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -4286460.604% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -391535.591% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -44949.659% |
| Neutra Corp. | 2851.00 USD | -118778675.061% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -10349.864% |
| PureTech Health plc | 693.97 Million USD | -387.97% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -41856.951% |
| IXICO plc | 15.84 Million USD | -21273.413% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -40788.467% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -3177.441% |
| CSL Limited | 38.02 Billion USD | 91.094% |
| Cellectis S.A. | 333.99 Million USD | -913.903% |